Recent Hematology/Oncology Faculty Publications (2010-2011)  

 

JOURNAL ARTICLES:

1.       Agrawal AK, Chang PP, Feusner J.  Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;33:e1-4.

2.       Agrawal AK, Haddad FG, Matsunaga A.  Acute nonimmune hemolytic anemia without fulminant hepatitis in Wilson disease. J Pediatr Hematol Oncol. 2011;33:e163-165.

3.       Agrawal AK, Hsu E, Quirolo K, Neumayr LD, Flori HR.  Red blood cell transfusion in pediatric patients with severe chronic anemia: How slow is necessary? Pediatr Blood Cancer. 2011.

4.       Agrawal AK, Saini N, Gildengorin G, Feusner JH.  Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies? Pediatr Blood Cancer. 2011;57:620-624.

5.       Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ.  Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010;85:6-13.

6.       Bloch E, Herwaldt B, Hagar RW.  A third described case of transfusion-transmitted babesia duncani: an additional consideration following transfusion. Transfusion. 2011 (submitted).

7.       Buchanan G, Vichinsky E, Krishnamurti L, Shenoy S.  Severe sickle cell disease--Pathophysiology and therapy. Biol Blood Marrow Transplant. 2010;16:S64-67.

8.       Chang P, Kang M, Xiao A, Chang J, Feusner J, Buffler P, Wiemels J.  FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer. 2010;10:513.

9.       Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A.  AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group. Cancer. 2011.

10.    Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W. Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) (E. Vichinsky collaborator).  Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer. 2010;55:485-494.

11.    DeBaun M, Frei-Jones M, Vichinsky E. Hemoglobinopathies. In: Kliegman R, ed. Nelson Textbook of Pediatrics (ed 19th). Philadelphia: ELSEVIER; 2011:1662-1676.

12.    Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, Kattamis A, Prossamariti L, Filosa A, Rund D, Gamberini MR, Cianciulli P, De Montalembert M, Gagliardotto F, Foster G, Grange JD, Cassara F, Iacono A, Cappellini MD, Brittenham GM, Prati D, Pietrangelo A, Craxi A, Maggio A.  Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116:2875-2883.

13.    Fung EB.  Nutritional deficiencies in patients with thalassemia. Ann N Y Acad Sci. 2010;1202:188-196.

14.    Fung EB, Aguilar C, Micaily I, Haines D, Lal A.  Treatment of vitamin D deficiency in transfusion-dependent thalassemia. Am J Hematol. 2011.

15.    Fung EB, Vichinsky EP, Kwiatkowski JL, Huang J, Bachrach LK, Sawyer AJ, Zemel BS.  Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone. 2011;48:1305-1312.

16.    Fung EB, Xu Y, Kwiatkowski JL, Vogiatzi MG, Neufeld E, Olivieri N, Vichinsky EP, Giardina PJ. Thalassemia Clinical Research Network.   Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr. 2010;157:641-647, 647 e641-642.

17.    Fung EB, Xu Y, Trachtenberg F, Olivieri N, Kwiatkowski J, Thompson A, Neufeld E, Boudreaux J, Quinn C, Vichinsky E. Thalassemia Clinical Research Network.  Inadequacy of dietary intake increases with age in patients with thalassemia. Journal of the American Diabetic Association. 2011 (accepted with revisions).

18.    Gabrovsky A, Aderinto A, Spevak M, Vichinsky E, Resar LM.  Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC disease. Pediatr Blood Cancer. 2010;54:148-150.

19.    Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, Kim-Shapiro DB, Machado R, Morris CR, Steinberg MH, Vichinsky EP.  Pulmonary hypertension and NO in sickle cell. Blood. 2010;116:852-854.

20.    Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk VR, Coles WA, Peters-Lawrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassarre J, Casella JF.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305:893-902.

21.    Gold JI, Treadwell M, Weissman L, Vichinsky E.  The mediating effects of family functioning on psychosocial outcomes in healthy siblings of children with sickle cell disease. Pediatr Blood Cancer. 2011.

22.    Gyang E, Yeom K, Hoppe C, Partap S, Jeng M.  Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease. Am J Hematol. 2011;86:104-106.

23.    Hazen RA, Eder M, Drotar D, Zyzanski S, Reynolds AE, Reynolds CP, Kodish E, Noll RB, Feusner (collaborator) J.  A feasibility trial of a video intervention to improve informed consent for parents of children with leukemia. Pediatric Blood & Cancer. 2010;55:113-118.

24.    Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L.  A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011;153:655-663.

25.    Hue-Roye K, Hipsky CH, Velliquette RW, Fuchisawa A, Lomas-Francis C, Hoppe C, Reid ME.  A novel RHCE*ce 48C, 733G allele with Nucleotide 941C in Exon 7 encodes an altered red blood cell e antigen. Transfusion. 2010;51:32-35.

26.    Hung K, Killilea D, Firnkes S, Ory D, Volitakis I, Hastings C, Bush A.  NPC1 modulates metal homeostasis: a metallomic analysis. Metallomics (submitted, May 2011). 2011.

27.    Jacobs JE, Hastings C.  Isolated extramedullary relapse in childhood acute lymphocytic leukemia. Curr Hematol Malig Rep. 2010;5:185-191.

28.    Jacobs JE, Quirolo K, Vichinsky E.  Novel influenza A (H1N1) viral infection in pediatric patients with sickle-cell disease. Pediatr Blood Cancer. 2011;56:95-98.

29.    James EB, Vreman HJ, Wong RJ, Stevenson DK, Vichinsky E, Schumacher L, Hall JY, Simon J, Golden DW, Harmatz P.  Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood cell transfusion therapy. Pediatr Hematol Oncol. 2010;27:112-121.

30.    Johnson RM, Ho YS, Yu DY, Kuypers FA, Ravindranath Y, Goyette GW.  The effects of disruption of genes for peroxiredoxin-2, glutathione peroxidase-1, and catalase on erythrocyte oxidative metabolism. Free Radic Biol Med. 2010;48:519-525.

31.    Kanathezhath B, Hazard FK, Guo H, Kidd J, Azimi M, Kuypers FA, Vichinsky EP, Lal A.  Hemoglobin Hakkari: an autosomal dominant form of beta thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene. Pediatr Blood Cancer. 2010;54:332-335.

32.    Kanathezhath B, Mizokami M, Stanislaus S, Hounshell C, Neumayr L, Guo H, Hearst JE, Walters MC, Kuypers FA.  Improved engraftment with minimal graft-versus-host disease after major histocompatibility complex-mismatched cord blood transplantation with photochemically treated donor lymphocytes. Exp Biol Med (Maywood). 2011;236:492-504.

33.    Kanathezhath B, Shah A, Secola R, Hudes M, Feusner JH.  The utility of routine surveillance blood cultures in asymptomatic hematopoietic stem cell transplant patients. J Pediatr Hematol Oncol. 2010;32:327-331.

34.    Kanathezhath B, Walters MC.  Umbilical cord blood transplantation for thalassemia major. Hematol Oncol Clin North Am. 2010;24:1165-1177.

35.    Kidd JL, Azimi M, Lubin B, Vichinsky E, Hoppe C.  Application of an expanded multiplex genotyping assay for the simultaneous detection of Hemoglobin Constant Spring and common deletional alpha-thalassemia mutations. Int J Lab Hematol. 2010;32:373-380.

36.    Klings E, Machado R, Barst R, Morris CR, Mubarak K, Gordeuk VR, Kato GJ, Ataga K, Gibbs JS, Castro O, Berman-Rosenzweig E, Sood N, Hsu L, Wilson KC, Telen M, DeCastro L, Krishnamurti L, Steinberg M, Badesch DB, Gladwin MT.  Consensus-based guidelines for the diagnosis and treatment of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2011 (under review).

37.    Kutny MA, Moser B, Laumann K, Feusner J.  FLT mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. 2011 (submitted).

38.    Kwiatkowski JL, Yim E, Miller S, Adams RJ, STOP II Study Investigators (E. Vichinsky collaborator).  Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 2011;56:777-782.

39.    Lal A, Ames BN.  Association of chromosome damage detected as micronuclei with hematological diseases and micronutrient status. Mutagenesis. 2011;26:57-62.

40.    Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP.  Heterogeneity of hemoglobin H disease in childhood. N Engl J Med. 2011;364:710-718.

41.    Lee WC, Rigante S, Pisano AP, Kuypers FA.  Large-scale arrays of picolitre chambers for single-cell analysis of large cell populations. Lab Chip. 2010;10:2952-2958.

42.    Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT.  Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118:855-864.

43.    MacMillan ML, Walters MC, Gluckman E.  Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies. Semin Hematol. 2010;47:37-45.

44.    Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, Fucharoen S, Cianciulli P, Grady RW, Prossomariti L, Porter JB, Iacono A, Cappellini MD, Bonifazi F, Cassara F, Harmatz P, Wood J, Gluud C.  Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011.

45.    Mansour KM, Kuypers FA, Wang TN, Miller AM, Larkin SK, Morris CR.  Secretory phospholipase A(2): a marker of infection in febrile children presenting to a pediatric ED. Am J Emerg Med. 2010.

46.    Morris CR.  Role of Arginase in Sickle Cell Lung Disease and Hemolytic Anemias. The Open Nitric Oxide Journal. 2010;2:41-54.

47.    Morris CR.  Vascular risk assessment in patients with sickle cell disease. Haematologica. 2011;96:1-5.

48.    Morris CR, Kim H-Y, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP.  Risks factors and mortality associated with an elevated tricuspid-regurgitant-jet-velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood. 2011.

49.    Morris CR, Vichinsky EP.  Pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2010;1202:205-213.

50.    Moyer JD, Nowak RB, Kim NE, Larkin SK, Peters LL, Hartwig J, Kuypers FA, Fowler VM.  Tropomodulin 1-null mice have a mild spherocytic elliptocytosis with appearance of tropomodulin 3 in red blood cells and disruption of the membrane skeleton. Blood. 2010;116:2590-2599.

51.    Neumayr L, Pringle S, Giles S, Quirolo KC, Paulukonis S, Vichinsky EP, Treadwell MJ.  Chart Card: feasibility of a tool for improving emergency department care in sickle cell disease. J Natl Med Assoc. 2010;102:1017-1023.

52.    Newaskar M, Hardy KA, Morris CR.  Asthma in sickle cell disease. ScientificWorldJournal. 2011;11:1138-1152.

53.    Olivieri NF, Pakbaz Z, Vichinsky E.  HbE/beta-thalassemia: basis of marked clinical diversity. Hematol Oncol Clin North Am. 2010;24:1055-1070.

54.    Olivieri NF, Saunthararajah Y, Thayalasuthan V, Kwiatkowski J, Ware RE, Kuypers FA, Kim HY, Trachtenberg FL, Vichinsky EP. Thalassemia Clinical Research Network.  A pilot study of subcutaneous decitabine in Beta-thalassemia intermedia. Blood. 2011;118:2708-2711.

55.    Pakbaz Z, Treadwell M, Kim HY, Trachtenberg F, Parmar N, Kwiatkowski JL, Cunningham MJ, Martin M, Sweeters N, Neufeld EJ, Giardina PJ, Olivieri N, Yamashita RC, Vichinsky E.  Education and employment status of children and adults with thalassemia in North America. Pediatr Blood Cancer. 2010;55:678-683.

56.    Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751-3757.

57.    Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ. Thalassemia Clinical Research Network (E. Vichinsky collaborator).  Renal dysfunction in patients with thalassaemia. Br J Haematol. 2011;153:111-117.

58.    Quinn CT, Stuart MJ, Kesler K, Ataga KI, Wang WC, Styles L, Smith-Whitley K, Wun T, Raj A, Hsu LL, Krishnan S, Kuypers FA, Setty Y, Rhee S, Key NS, Buchanan GR, (E. Vichinsky collaborator).  Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol. 2011.

59.    Quirolo K.  How do I transfuse patients with sickle cell disease? Transfusion. 2010;50:1881-1886.

60.    Rienhoff HY, Jr., Viprakasit V, Tay L, Harmatz P, Vichinsky E, Chirnomas D, Kwiatkowski JL, Tapper A, Kramer W, Porter JB, Neufeld EJ.  A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 2011;96:521-525.

61.    Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, Wingard JR, Fasth A, Lo Nigro L, Ayas M, Purtill D, Boudjedir K, Chaves W, Walters MC, Wagner J, Gluckman E, Rocha V.  Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17:1375-1382.

62.    Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK, Irfan SM, Bredeson CN, Cowan MJ, Gale RP, Hale GA, Horan J, Hongeng S, Eapen M, Walters MC.  HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood. 2010;117:1745-1750.

63.    Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JGt, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR.  Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation. 2011.

64.    Satter EK, Walters MC, Hurt M, Bolton JG, Dever T.  A brief overview of the most common histiocytic disorders. G Ital Dermatol Venereol. 2010;145:717-731.

65.    Shepherd JA, Fan B, Lu Y, Marquez L, Salama K, Hwang J, Fung EB.  Dual-energy X-ray absorptiometry with serum ferritin predicts liver iron concentration and changes in concentration better than ferritin alone. J Clin Densitom. 2010;13:399-406.

66.    Singer ST, Sweeters N, Vega O, Higa A, Vichinsky E, Cedars M.  Fertility potential in thalassemia major women: current findings and future diagnostic tools. Ann N Y Acad Sci. 2010;1202:226-230.

67.    Singer ST, Vichinsky EP, Gildengorin G, van Disseldorp J, Rosen M, Cedars MI.  Reproductive capacity in iron overloaded women with thalassemia major. Blood. 2011;118(10):2878-81.

68.    Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.  Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. Br J Haematol. 2011;Jul;154(2):281-4.

69.    Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (E. Vichinsky collaborator).  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med. 2011; May;12(5):697-705.

70.    Sobota A, Yamashita R, Xu Y, Trachtenberg F, Kohlbry P, Kleinert DA, Giardina PJ, Kwiatkowski JL, Foote D, Thayalasuthan V, Porter JB, Thompson AA, Schilling L, Quinn CT, Neufeld EJ. Thalassemia Clinical Research Network (E. Vichinsky collaborator).  Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2010;86:92-95.

71.    Sohn EY, Noetzli LJ, Gera A, Kato R, Coates TD, Harmatz P, Keens TG, Wood JC.  Pulmonary function in thalassaemia major and its correlation with body iron stores. Br J Haematol. 2011;155:102-105.

72.    Soupene E, Dinh NP, Siliakus M, Kuypers FA.  Activity of the acyl-CoA synthetase ACSL6 isoforms: role of the fatty acid Gate-domains. BMC Biochem. 2010;11:18.

73.    Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up (E. Vichinsky collaborator).  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85:403-408.

74.    Stewart AK, Shmukler BE, Vandorpe DH, Rivera A, Heneghan JF, Li X, Hsu A, Karpatkin M, O'Neill AF, Bauer DE, Heeney MM, John K, Kuypers FA, Gallagher PG, Lux SE, Brugnara C, Westhoff CM, Alper SL.  Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. Am J Physiol Cell Physiol. 2011.

75.    Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010;116:5650-5659.

76.    Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C.  A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease. J Pain Symptom Manage. 2010;40:416-435.

77.    Thompson AA, Cunningham MJ, Singer ST, Neufeld EJ, Vichinsky E, Yamashita R, Giardina P, Kim HY, Trachtenberg F, Kwiatkowski JL. Thalassemia Clinical Research Network.  Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol. 2011;153:121-128.

78.    Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, Kwiatkowski J, Thompson AA, Porter J, Coates T, Giardina PJ, Olivieri N, Yamashita R, Neufeld EJ. Thalassemia Clinical Research Network.  Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86:433-436.

79.    Trachtenberg F, Foote D, Martin M, Carson S, Coates T, Beams O, Vega O, Merelles-Pulcini M, Giardina P, Kleinert DA, Kwiatkowski J, Thompson A, Neufeld E, Schilling L, Thayalasuthan V, Pakbaz Z, Yamashita R. Thalassemia Clinical Research Network (E. Vichinsky collaborator).  Pain as an emergent issue in thalassemia. Am J Hematol. 2010;May;85(5):367–370.

80.    Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I.  Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol. 2011;86:116-120.

81.    Treadwell MJ, Alkon A, Quirolo KC, Boyce WT.  Stress reactivity as a moderator of family stress, physical and mental health, and functional impairment for children with sickle cell disease. J Dev Behav Pediatr. 2010;31:491-497.

82.    Treadwell MJ, Alkon A, Styles L, Boyce WT.  Autonomic nervous system reactivity: children with and without sickle cell disease. Nurs Res. 2011;60:197-207.

83.    Trobaugh-Lotrario AD, Finegold MJ, Feusner JH.  Rhabdoid tumors of the liver: rare, aggressive, and poorly responsive to standard cytotoxic chemotherapy. Pediatr Blood Cancer. 2011;57:423-428.

84.    Vichinsky E.  Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Ann N Y Acad Sci. 2010;1202:180-187.

85.    Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T.  Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154:387-397.

86.    Vichinsky EP, Neufeld EJ.  Preface to Cooley's Anemia: Ninth Symposium. Ann N Y Acad Sci. 2010;1202:ix-x.

87.    Vichinsky EP, Neumayr LD, Gold JI, Weiner MW, Rule RR, Truran D, Kasten J, Eggleston B, Kesler K, McMahon L, Orringer EP, Harrington T, Kalinyak K, De Castro LM, Kutlar A, Rutherford CJ, Johnson C, Bessman JD, Jordan LB, Armstrong FD.  Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303:1823-1831.

88.    Vichinsky EP, Ohene-Frempong K.  Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. Pediatr Hematol Oncol. 2011;28:37-42.

89.    Vichinsky EP, Ohene-Frempong K, Thein SL, Lobo CL, Inati A, Thompson AA, Smith-Whitley K, Kwiatkowski JL, Swerdlow PS, Porter JB, Marks PW.  Transfusion and chelation practices in sickle cell disease: a regional perspective. Pediatr Hematol Oncol. 2011;28:124-133.

90.    Wahl S, Gildengorin G, Feusner J.  Weekend Delay in Initiation of Chemotherapy for Acute Lymphoblastic Leukemia (ALL): Does it Matter? J Pediatr Hematol Oncol. 2011 (in press).

91.    Wahl S, Garcia A, Hagar RW, Gildengorin G, Quirolo K, Vichinsky E.  Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions. Transfusion. 2011 (in review).

92.    Wahl S, Vichinsky E.  Pulmonary hypertension in hemolytic anemias. F1000 Med Rep. 2010;2.

93.    Walter PB, Porter J, Evans P, Kwiatkowski J, Neufeld E, Coates T, Giardina P, Grady RW, Vichinsky E, Olivieri N, Trachtenberg F, Alberti D, Fung EB, Ames BN, Higa A, Harmatz P.  Increased leukocyte apoptosis in Beta-thalassemia patients. Haematologica. 2011 (under review).

94.    Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, Haut PR, Horan J, Hsu LL, Kamani N, Levine JE, Margolis D, Ohene-Frempong K, Patience M, Redding-Lallinger R, Roberts IA, Rogers ZR, Sanders JE, Scott JP, Sullivan KM.  Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263-272.

95.    Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, Brown C, Qureshi A, Bigelow C, Neumayr L, Smith-Whitley K, Chui DH, Delahunty M, Woolson R, Steinberg M, Telen M, Kesler K.  The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial (E. Vichinsky collaborator). Br J Haematol. 2011;152:771-776.

96.    Wang ZJ, Fischer R, Chu Z, Mahoney DH, Jr., Mueller BU, Muthupillai R, James EB, Krishnamurthy R, Chung T, Padua E, Vichinsky E, Harmatz P.  Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia. Magn Reson Imaging. 2010;28:363-371.

97.    Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD.  Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol. 2010;85:818-819.

98.    Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD.  Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011;96:1055-1058.

99.    Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD.  The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116:537-543.

100.Zohdi TI, Kuypers FA, Lee WC.  Estimation of red blood cell volume fraction from overall permittivity measurements. International Journal of Engineering Science. 2011;48:1681-1691.

 

EDITED BOOKS:

1.     Vichinsky E, Neufeld E eds. Cooley's Anemia: Ninth Symposium. Annals of the New York Academy of Sciences. Vol. 1202. Boston: Blackwell Publishing; 2010.

 

BOOK CHAPTERS:

1.     Ataga K, Vichinsky E. Thrombotic complications in sickle cell disease. In: Aird W, Bennett JM, Schulman S, White G, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice (ed Sixth (December 2012)): Lippincott Williams & Wilkins; 2011 (in press).

2.    DeBaun M, Frei-Jones M, Vichinsky E. Chapter 456 - Hemoglobinopathies. In: Kliegman R, ed. Nelson Textbook of Pediatrics (ed 19th): Saunders; 2011.

3.    Hagar W, Morris CR. Adults with Sickle-Cell Disease: Implications of Increasing Longevity. In: Venkat A, ed. Challenging and Emerging Conditions in Emergency Medicine: Wiley-Blackwell; 2011:115-140.

4.    Hastings C, Agrawal A, Lubin B, Feusner J. Hematologic supportive care for the child with cancer. In: Pizzo P, Poplack D, eds. Principles and Practice of Pediatric Oncology (ed Sixth; October 11, 2010): Lippincott Williams & Wilkins; 2010:1152-1190.

5.    Lal A, Vichinsky E. Sickle Cell Disease. In: Hoffbrand V, Catovsky D, Tuddenham E, Green ACD, eds. Postgraduate Haematology (ed 6th). Oxford, UK: Blackwell Publishing; 2011:109-124.

6.    Morris CR. Sickle Cell Emergencies. In: Ewen Amieva-Wang N, ed. A Practical Guide to Pediatric Emergency Medicine: Caring for Children in the Emergency Department: Cambridge University Press; 2011:876.

7.    Morris CR, Gladwin MT. Hemolysis-associated pulmonary hypertension in sickle cell disease and thalassemia. In: Peacock AJ, Naeije R, Rubin LJ, eds. Pulmonary Circulation (ed 3rd): Hodder Arnold; 2011:728.

8.    Morris CR, Hagar RW. Adults with sickle-cell disease: implications of increasing longevity. In: Venkat A, ed. Challenging and Emerging Conditions in Emergency Medicine: Wiley-Blackwell; 2011:376.

 

EDITORIALS:

1.    Walters MC.  Gene therapy and bone marrow transplantation for thalassemia: changing of the guard? Mol Ther. 2010;18:1577.

 

AUDIO/VISUAL MEDIA:

1.    Vichinsky E, Porter J. CancerMinds: Optimizing Chelation Therapy for Pediatric Iron Overload: Emerging Strategies: ReachMD XM Radio; April 26, 2010.  http://www.reachmd.com/cmedetails.aspx?sid=5450.

 

LETTERS:

1.       Agrawal AK, Feusner JH.  Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia? Br J Haematol. 2011.

2.       Morris CR.  Reduced Global Arginine Bioavailability: A Common Mechanism of Vasculopathy in SCD and PH. A response to "Pulmonary hypertension and nitric oxide depletion in sickle cell disease", Bunn, H. Franklin. Published online April 28, 2010.. Blood. 2010;116:5.  http://bloodjournal.hematologylibrary.org/cgi/eletters/blood-2010-02-268193v1

3.       Vichinsky E.  Pulmonary hypertension is an important problem in sickle cell disease. A response to "Pulmonary hypertension and nitric oxide depletion in sickle cell disease", Bunn, H. Franklin. Published online April 22, 2010. Blood. 2010;116:5.   http://bloodjournal.hematologylibrary.org/content/116/5/687.short/reply#bloodjournal_el_153

4.       Walters MC, Sullivan KM.  Stem-cell transplantation for sickle cell disease. N Engl J Med. 2010;362:955-956; author reply 956.


ABSTRACTS and REVIEWS:

1.       Aguilar AE, Agrawal AK, Feusner J. Central nervous system relapse in pediatric acute lymphoblastic leukemia: Should we be making the diagnosis sooner? American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illinois; June 3 - 7, 2011.

2.       Agrawal A, Saini N, Gildengorin G, Feusner J. Is routine computed tomographic scanning justified in the early days of persistent febrile neutropenia in children with malignancies? American Society of Pediatric Hematology Oncology (ASPHO) 23rd Annual Meeting. Pediatr Blood Cancer 2010; 54(6); poster presentation. Montréal, Quebec, Canada; April 7-10, 2010.

3.       Anurag K, Agrawal A, Quirolo K, Neumayr L, Flori HR. Rate of packed red blood cell transfusion in pediatric patients with severe chronic anemia and normal cardiopulmonary status: how slow is truly necessary? American Society of Pediatric Hematology Oncology (ASPHO) 23rd Annual Meeting. Pediatr Blood Cancer 2010; 54(6); poster presentation 122. Montréal, Quebec, Canada; April 7-10, 2010.

4.       Barredo J, Hastings C, Xiaomin Lea. Inferior outcome with reduced dose cranial radiation (12 Gy) in isolated CNS relapse of ALL treated with intensive systemic chemotherapy: A Children's Oncology Group study. 43rd Congress of the International Society of Paediatric Oncology. Auckland, New Zealand; October 26-30, 2011.

5.       Barst RJ, Kato GJ, Sachdev V, Nouraie M, Machado RF, Hassell K, Gibbs S, Little J, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Badesch DB, Lanzkron S, Castro O, Rosenzweig EB, Goldsmith JC, Gladwin M, Gordeuk VR. Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 947.

6.       Chu J, Guo H, Raphael R, Torkildson J, Vichinsky E, Hastings C. Disseminated juvenile xanthogranuloma culminating in bone marrow failure and death. American Society of Pediatric Hematology Oncology (ASPHO) 24th Annual Meeting. Baltimore, Maryland; April 13-16, 2011.

7.       Detterich J, Noetzli L, Carson S, Harmatz P, Coates TD, Wood JC. Pulmonary Hypertension Is Uncommon In Well-Transfused Thalassemia Major Patients. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 4273.

8.       Donthineni R, Earl J, Neumayr L, Hagar RW, Quirolo KC, Aguilar C, Vichinsky E. A New Method of Hip Coring Decompression for the Treatment of Femoral Avascular Necrosis In Sickle Cell Disease: Perioperative Safety and Preliminary Efficacy Data. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 264.

9.       Douer D, Feusner J, et al. Late relapses following All-trans retinoic acid for Acute Promyelocytic Leukemia are uncommon, respond well to salvage therapy and occur independently of prognostic factors at diagnosis: Long-term follow-up of North American Intergroup Study I0129. The 53rd Annual Meeting of the American Society of Hematology. San Diego, CA; December 10-13, 2011.

10.    Earl J, Sun P, Martin K, Quirolo K, Vichinsky E, Hoppe C. Evaluation of Moyamoya Disease in Sickle Cell Anemia Patients After Encephaloduroarteriosynangiosis. The 53rd Annual Meeting of the American Society of Hematology. San Diego, California; December 10-13, 2011.

11.    Feusner JH. Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Study C9710. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illinois; June 4-8, 2010.

12.    Freyer DR, Zung L, Reichman L, Feusner J, Finklestein J, Ruccione K, Gaynon P. Early decline in left ventricular (LV) function in survivors of acute myeloid leukkemia (AML) treated with an anthracycline-intensive regimen. American Society of Pediatric Hematology Oncology (ASPHO) 24th Annual Meeting. Baltimore, Maryland; April 13-16, 2011.

13.    Fung E, Xu Y, Vichinsky E, Trachtenberg F, Porter J, Neufeld E, Olivieri N, Quinn C, Kwiatkowski J, Boudreaux J, Odame I, Thompson A. Inadequate Dietary Intake in Patients with Thalassemia. American Society of Pediatric Hematology Oncology (ASPHO) 23rd Annual Meeting. Montréal, Quebec, Canada; April 7-10, 2010.

14.    Fung EB, Kwiatkowski J, Huang J, Gildengorin G, King JC, Vichinsky E. Zinc Supplementation Improves Bone Density in Patients with Thalassemia. Children's Hospital Oakland Research Institute Annual Symposium - 50th Anniversary. Award for outstanding oral presentation. Oakland, CA; 2010.

15.    Fung EB, Kwiatkowski J, Huang J, Gildengorin G, Vichinsky E, King J. Zinc Supplementation Improves Bone Density in Patients with Thalassemia. American Society of Pediatric Hematology/Oncology 23rd Annual Meeting Pediatric Blood & Cancer (ed Volume 54, Issue 6). Quebec, Canada April 7-10, 2010: 797.

16.    Fung EB, Reget K, Haines D, Sawyer A, Lal A. Exploring vertebral abnormalities in patients with thalaseemia and sickle cell disease The 53rd Annual Meeting of the American Society of Hematology. San Diego, California; December 10-13, 2011.

17.    Fung EB, Reget K, Haines D, Sawyer AJ, Lal A. Examing vertebral abnormalities in patients with hemoglobinopathies. Orthopedic Research Society Annual Meeting. Long Beach, California; January 13-16, 2011.

18.    Fung EB, Xu Y, Olivieri N, Giardina P, Porter J, Kwiatkowski J, Odame I, Thompson A, Neufeld E, Boudreaux J, Quinn C, Trachtenberg F, Vichinsky E, King J. Inadequate dietery intake in patients with thalassemia. American Society of Pediatric Hematology/Oncology 23rd Annual Meeting Pediatric Blood & Cancer (ed Volume 54, Issue 6). Quebec, Canada April 7-10, 2010: 799.

19.    Gallagher RE, Moser BK, Racevskis J, Poire X, Bloomfield CD, Carroll AJ, Ketterling R, Ralston D, Schachter-Tokarz E, Zhou D, Chen I-ML, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Appelbaum FR, Larson RA, Powell BL, Paietta E, Willman CL, Stock W. Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 1038.

20.    Gariepy C, Lal A, Fung E. Reduced Physical Activity In Adult and Pediatric Patients with Thalassemia. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 5174.

21.    Giardina P, Goldberg S, Parkhurst Cain J, Chirnomas D, Esposito J, Paley C, Vichinsky E. The palatability and tolerability of Deferasirox (EXJADE®) taken with meals, different liquids, or crushed and added to food. American Society of Pediatric Hematology Oncology (ASPHO) 24th Annual Meeting. Baltimore, Maryland; April 13-16, 2011: 4924: poster presentation.

22.    Goel R, Hassell K, Castro O, Barst RJ, Rosenzweig EB, Sachdev V, Machado RF, Gibbs S, Little JA, Schraufnagel DE, Girgis RE, Morris CR, Badesch DB, Lanzkron S, Goldsmith JC, Gordeuk VR, Kato GJ, Gladwin M, Krishnamurti L. Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 4804.

23.    Goldberg SL, Giardina P, Cain JP, Chirnomas D, Esposito J, Paley CS, Vichinsky E. The Palatability and Tolerability of Deferasirox (Exjade(R)) Taken with Meals, Different Liquids, or Crushed and Added to Food. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 5155.

24.    Gonzalez A, Hagar RW, Hoehner C, Fung E. Liver iron, Vitamin D, and bone mineralization in sickle cell disease. CHORI Summer Student Symposium. Oakland, California: poster presentation.

25.    Green NS, Ender K, Pashankar F, Driscoll C, Giardina P, Mullen CA, Clark L, Crotty J, Burney M, Hoppe C, Barral S. Genetics of HbF and HbF Response to Hydroxyurea In Pediatric Sickle Cell Disease: A Multi-Site Pilot Analysis of Candidate SNP Variants. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 2641.

26.    Hagar RW. The burden of sickle cell pain. Sickle Cell Adult Provider Network Annual Symposium. Hollywood, Florida: oral presentation.

27.    Hagar RW. Chronic renal disease in adult sickle cell patients. 5th Annual Sickle Cell Disease Research and Educational Symposium and Annual National Sickle Cell Scientific Meeting. Hollywood, Florida: oral presentation.

28.    Hagar RW, Kurio G, Hoehner C, Earl J, Neumayr L. Cardiac iron in hypertransfused sickle cell patients. 5th Annual Sickle Cell Disease Research and Educational Symposium and Annual National Sickle Cell Scientific Meeting. Hollywood, Florida: oral presentation.

29.    Haines D, Carson S, Green S, Martin M, Coates TD, Vega OO, Gerstenberger E, Braunstein J, Calamaras D, Dzackova R, Giardina P, Klienert D, Kwiatkowski J, Mendoza TR, Merelles-Pulcini M, Neufeld EJ, Olivieri NF, Schilling L, Vichinsky E, Trachtenberg F. Phenomenon of Pain In Thalassemia: A Prospective Analysis by the Thalassemia Clinical Research Network (TCRN). American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 256.

30.    Hastings C, Killilea D, Suh J, Browne R. Clinical experience and biomarker assessment with intravenous and intrathecal infusions of hydroxyl-propyl-beta-cyclodextrin in identical twin patients with Niemann-Pick Type C Disease. 2011 Scientific Conference on Niemann-Pick Type C Disease. Notre Dame, Indiana; June 9-11, 2011: oral presentation.

31.    Hastings C, Torkildson J, Raphael R. Intrathecal hydroxyl-propyl-beta-cyclodextrix reverses hearing loss in identifal twin girls with Niemann-Pick Type C Disease. 12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics. Montreal, Canada; October 11-15, 2011: Poster #1315T.

32.    Heeney M, Mueller B, Baltz B, Paley C, Esposito J, Sharma S, Vichinsky E. Baseline characteristics of patients with sickle cell disease in an ongoing 5-year, prospective, noninterventional registry trial. The 53rd Annual Meeting of the American Society of Hematology. San Diego, CA; Dec 10-13, 2011.

33.    Kanathezhath B, Feusner J.  Evaluation of: [Delaney C et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010 Feb; 16(2):232-6; doi: 10.1038/nm.2080]. Faculty of 1000. 2010;31 Aug 2010.   Http://F1000.com/1821956

34.    Kanathezhath B, Feusner J.  Evaluation of: [Khorana AA et al. Can literature enhance oncology training? A pilot humanities curriculum. J Clin Oncol. 2011 Feb 1; 29(4):468-71; doi: 10.1200/JCO.2010.33.3617]. Faculty of 1000. 2011;11 Mar 2011.   Http://F1000.com/8865959

35.    Kanathezhath B, Larkin SK, Kaplan J, Walters MC, Kuypers F. Augmented Regulatory T Cell Response After Photochemical Treatment Alleviates Acute Graft-Versus-Host Disease and Improves Survival. American Society of Hematology Annual Meering. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 3740.

36.    Kanathezhath B, Mizokami M, Hounshell C, Neumayr L, Guo H, Walters M, Kuypers F. Improved hematopoietic engraftment without graft versus host disease by "add-back" of photochemically treated T lymphocutes in mismatched cord blood transplantation. The American Society for Blood and Marrow Transplantation, BMT Tandem Meeting (ed oral presentation). Orlando, Florida; February 26-27, 2010.

37.    Kanathezhath B, Neumayr L, Guo H, Walters M, Kuypers F. Augmentation Of Hematopoietic Engraftment Without Graft Versus Host Disease By “Add-Back” Of Photochemically Treated T Lymphocytes In Mismatched Cord Blood Transplantation. The American Society for Blood and Marrow Transplantation, BMT Tandem Meeting. Biology of Blood and Marrow Transplantation (ed Issue 2, Supplement). Orlando, Florida; February 26-27, 2010: S160-S161.

38.    Kanathezhath B, Stanislaus S, Kaplan J, Larkin S, Kuypers F, Walters M. Augmented Regulatory T Cell Response After Photochemical Treatment Alleviates Acute Graft-Versus Host Disease and Improves Survival The American Society for Blood and Marrow Transplantation, BMT Tandem Meeting. Biology of Blood and Marrow Transplantation (ed Issue 2, Supplement). Honolulu, Hawaii; February 17-21, 2011: S331-S332.

39.    Killilea D, Suh J, Mattson N, Zetterberg H, Portelius E, Blennow K, Hung Y, Bush A, Hastings C. Characterization of biomarkers during investigative therapy of hydroxyl-propyl-beta-cyclodextrin in Niemann-Pick Type C Disease. 12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics. Montreal, Canada; October 11-15, 2011: Poster #1299W.

40.    Klaassen R, Merells-Pulcini M, Barrowman N, Vichinsky E, Sweeters N, Kirby M, Neufeld E, Kwiatkowski J, Wu J, Vickars L, Blanchette V, Forgie M, Yamashita R, Wong-Rieger D, Young N. COP 36902:  Health-Related Quality of Life of Oral Versus Subcutaneous Chelation in Beta Thalassemia Major. The 53rd Annual Meeting of the American Society of Hematology. San Diego, CA; December 10-13, 2011.

41.    Klaassen R, Vichinsky E, Kirby M, Neufeld E, Kwiatkowski J, Wu J, Vickars L, Barrowman N, Merelles-Pulcini M, Yamashita R, Wong-Rieger D, Young NL, Sweeters N. Validation and reliability of a disease-specific quality-of-life measure (the TranQol) in adults with thalassemia major. International Society for Quality of Life Research18th Annual Conference. Denver, Colorado; October 26-29, 2011.

42.    Kleinert D, Goldberg S, Parkhurst J, Chimomas D, Esposito J, Paley C, Vichinsky E, Giardina P. A single-arm, open-label study of the palatability and tolerability of deferasirox (Exjade) taken with meals, different liquids, or crushed and added to food. Association of Pediatric Hematology/Oncology Nurses (APHON) 36th Annual Conference & Exhibit. Anaheim, California; September 8-10, 2011.

43.    Krishnamurti L, Goel R, Castro O, Barst RJ, Rosenzweig EB, Sachdev V, Machado RF, Gibbs S, Little JA, Schraufnagel DE, Girgis RE, Morris CR, Badesch DB, Lanzkron S, Goldsmith JC, Gordeuk VR, Kato GJ, Gladwin M, Hassell K. Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 2658.

44.    Kutlar A, Ataga KI, Reid M, Blair-Britt LA, Vichinsky E, Neumayr L, Labotka RJ, Glass J, Small-WIlliams A, Keefer J, Shen L, Boosalis MS, Thomson A, Bobbitt P, Wallis W, Johnson E, Berenson RJ, Perrine SP. Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 943; oral presentation.

45.    Kutny MA, Moser BK, Gregory J, Woods WG, Feusner JH, Meshinchi S. FLT3 Mutations Are Prevalent and Are Significantly Associated with Induction Death In Pediatric Acute Promyelocytic Leukemia, a Report From the Children's Oncology Group. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 753.

46.    Lal A, Goldrich ML, Foote D, Azimi M, Singer ST, Vichinsky E. Hemoglobin H disease during childhood. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 4260.

47.    Lal A, Goldrich ML, Foote D, Azimi M, Singer ST, Vichinsky E. Longitudinal Follow-up From Newborn Screening Reveals Deletional Hemoglobin H Disease and Hemoglobin H Constant Spring Disease Are Distinct Thalassemia Syndromes. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: Poster presentation: 4260.

48.    Lal A, Micaily I, Foote D, Fung E. A Simple Regimen to Correct Vitamin D Deficiency In Transfusion-Dependent Thalassemia with High-Dose Ergocalciferol. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 4261.

49.    Lal A, Sweeters N, Ng V, Foote D, Evans P, Neumayr L, Kurio G, Harmatz P, Porter JB, Vichinsky E. Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: Poster presentation: 4269.

50.    Lal A, Sweeters N, Ng V, Haines D, Neumayr L, Kurio G, Harmatz P, Evans P, Porter JB, Vichinsky E. Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia. 12th International Conference on Thalassemia. Antalya, Turkey: Thalassemia International Federation; May 11-14, 2011.

51.    Machado RF, Barst RJ, Yovetich NA, Hassell KA, Goldsmith JC, Woolson R, Gordeuk VR, Gibbs S, Little JA, Kato GJ, Schraufnagel DE, Krishnamurti L, Girgis R, Morris CR, Berman-Rosenzweig E, Badesch DB, Waclawiw MA, Gladwin MT. Evaluation of Sildenafil Therapy for Patients with Sickle Cell Disease and Increased Tricuspid Regurgitant Velocity: Preliminary Results of the Walk-PHaSST Trial. American Thoracic Society International Conference. Oral Presentation, [B16] PULMONARY ARTERIAL HYPERTENSION: FROM ASSESSING RISK TO THERAPEUTIC RESULTS. New Orleans, Louisiana; May 14-19, 2010.

52.    Marsh A, Lo L, Feusner J. Sorafenib (Soraf) and bevacizumab (Beva) for recurrent metastatic hepatoblastoma (HB). American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, Illinois; June 3-7, 2011.

53.    Mietus-Snyder M, Jung S, Ames BN, Flores B, Lal A. Metabolic abnormalities in obese teens may relate to poor diets. American Heart Association Nutrition, Physical Activity and Metabolism / Cardiovascular Disease Epidemiology and Prevention and Nutrition, Physical Activity, and Metabolism  (AHA EPI-NPAM) 2011 Scientific Sessions. Atlanta, Georgia; March 22 - 25, 2011.

54.    Morris CR, Ansari M, Lavrisha L, Sweeters N, Kuypers F, Vichinsky E. Arginine therapy: a promising intervention for vaso-occlusive pain episodes in sickle cell disease. the 6th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide. Sakyo-ku, Kyoto, Japan; June 14-June 18, 2010.

55.    Morris CR, Kim H-Y, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP. Risks Factors and Mortality Associated with Doppler-Defined-Pulmonary Hypertension In Thalassemia Major: a Report From the Thalassemia Clinical Research Network Longitudinal Cohort Study. American Thoracic Society International Conference. Denver, Colorado; May 13-18, 2011: A6441.

56.    Morris CR, Kuypers F, Hagar RW, Ansari M, Larkin A, Lavrisha L, Wardlaw M, Zheu A, Vichinsky E, Suh J. Oral glutamine supplementation improves global arginine bioavailability in patients with sickle cell disease and Doppler-defined pulmonary hypertension: Preliminary pharmacokinetic results. 5th Annual Sickle Cell Disease Research and Educational Symposium & Annual National Sickle Cell Disease Scientific Meeting - Symposium and Scientific Meeting. Hollywood, Florida; February 23-25, 2011.

57.    Morris CR, Kuypers F, Hagar RW, Ansari M, Larkin SK, Lavrisha L, Wardlaw M, Zhou A, Vichinsky E, Suh JH. Metabolic Fate of Oral Glutamine Supplementation within Plasma and Erythrocytes of Patients with Sickle Cell Disease: Preliminary Pharmacokinetics Results. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 1636- poster presentation.

58.    Morris CR, Kuypers FA, Hagar RW, Ansari M, Larkin S, Lavrisha L, Zhou A, Vichinsky E, Suh J. Metabolic Fate Of Oral Glutamine Supplementation Within Plasma And Erythrocytes Of Patients With Sickle Cell Disease And Pulmonary Hypertension: Preliminary Pharmacokinetics Results. American Thoracic Society International Conference. Denver, Colorado; May 13-18, 2011: A5917.

59.    Morris CR, Ansari M, Lavrisha L, Sweeters N, Kuypers FA, Vichinsky EP. L-Arginine: A Promising Nitric Oxide-Based Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease (SCD). Nitric Oxide Society Sixth International Conference: Biology, Chemistry, and Therapeutic Applications of Nitric Oxide. Kyoto, Japan: Nitric Oxide-Biology and Chemistry; Jun 14-18, 2010: S25-S26.

60.    Nouraie M, Barst RJ, Rosenzweig EB, Sachdev V, Machado RF, Hassell K, Gibbs JSR, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Badesch DB, Lanzkron S, Castro O, Goldsmith JC, Gladwin M, Gordeuk VR, Kato GJ. NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, FL; November 19, 2010: 1639.

61.    Olivieri NF, Saunthararajah Y, Thayalasuthan V, Kwiatkowski J, Ware RE, Kuypers F, Kim H-Y, Vichinsky EP. A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat Beta-Thalassemia Intermedia. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 2078- poster presentation.

62.    Paulukonis S, Neumayr L, Coates TD, Vichinsky E, Feuchtbaum L. Emergency Room Utilization by California Sickle Cell Patients During Pediatric to Adult Care Transition. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 254; poster presentation.

63.    Powell B, Feusner J, et al. Adding mercaptopurine and methotrexate to alternate week ATRA maintenance therapy does not improve the outcome for adults with Acute Promyelocytic Leukemia (APL) in first remission: Results from North American Leukemia Intergroup Trial C9710. The 53rd Annual Meeting of the American Society of Hematology. San Diego, CA; December 10-13, 2011.

64.    Rienhoff HY, Jr, Viprakasit i, Tay LH, Harmatz P, Vichinsky E, Chirnomas D, Kwiatkowski J, Tapper AE, Porter JB, Neufeld EJ. A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 2057- poster presentation.

65.    Shenoy S, Asselin B, Dalal J, Goyal R, Kaufman JL, Loeb D, McCarty J, Robertson K, Strahlendorf C, Walters MC, Angell J, Huebner D, Shaw PJ. Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil(R)) + G-CSF In Pediatric Patients with Malignant Disorders. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 2245.

66.    Shepherd JA, Fan B, Lu Y, Marquez L, Salama K, Hwang J, Fung EB. DXA with serum ferritin predicts liver iron concentration and change in concentration better than ferritin alone. International Society for Clinical Densitometry Annual Meeting. San Antonio, Texas; March 2010.

67.    Simon SI, Chase S, Larkin SK, Kuypers F, Styles L, Wun T, Thackray H, Magnani JL. Effects of Selectin Antagonist GMI-1070 on the Activation State of Leukocytes In Sickle Cell Patients Not In Crisis. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 2672.

68.    Singer ST, Kuypers F, Fineman J, Larkin SK, Jeng M, Harmon C, Sweeters N, Higa A, Vichinsky E. The Effect of Thalassemia and Other RBC Hemolytic Disorders and Splenectomy on the Frequency of Pulmonary Hypertension. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 2077- poster presentation.

69.    Thompson A, Kim H, Calamaras D, Beatty J, Singer ST, Vichinsky E, Braunstein J, Yamashita R, Giardina P, Olivieri N, Parmar N, Trachtenberg F, Neufeld E, Kwiatkowski J. Thalassemia Clinical Research Network. Pregnancy outcomes in women with thalassemia in North America and the UK. 12th International Conference on Thalassemia. Antalya, Turkey: Thalassemia International Federation; May 11-14, 2011.

70.    Treadwell M, Barreda F, Major K, Walker V, Payton W, Kaur K, Vichinsky E. Mental Health Symptoms, Quality of Life and Barriers to Accessing Health Care in Sickle Cell Disease. The 53rd Annual Meeting of the American Society of Hematology. San Diego, CA; December 10-13, 2011.

71.    Treadwell M, Levine RE, Keller SD, Hassell K, Werner E. Understanding perspectives of adults with sickle cell disease in developing a disease-specific quality of life measurement system. International Society for Quality of Life Research17th Annual Conference. London, England; October 27-30, 2010.

72.    Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane PA, Mathias L, Porter JB, Tebbi CK, Wilson FL, Griffel L, Deng W, Giannone V, Coates TD. Long-Term Safety and Efficacy of Deferasirox (Exjade(R)) In Transfused Patients with Sickle Cell Disease Treated for up to 5 Years. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, FL; November 19, 2010: 845; oral presentation.

73.    Vichinsky E, Chu J, Walters M, Lal A, Singer ST, Foote D, Shiota S. Successful Hematopoietic Cell Transplantation for Alpha Thalassemia Major. American Society of Pediatric Hematology Oncology. Montréal, Quebec, Canada; April 7-10, 2010: Poster presentation: 267.

74.    Vichinsky E, Neumayr L, Gold JI, Weiner MW, Kasten J, Truran D, Snyder C, Kesler K, Hussein AM, Harrington TJ, McMahon L, Gordeuk VR, Kutlar A, Orringer EP, De Castro LM, Field J, Swerdlow PS, Bessman JD, Snyder R, Strouse JJ, Armstrong FD. A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease. American Society of Hematology Annual Meeting. ASH Annual Meeting Abstracts. Orlando, Florida; November 19, 2010: 3221- poster presentation.

75.    Vichinsky E, Torres M, Glass J, Minniti C, Barrette S, Habr D, Lynch N, Yiyun Z, Files B. A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy The 53rd Annual Meeting of the American Society of Hematology. San Diego, California; December 10-13, 2011.

76.    Vichinsky EP.  Medical Management Of Sickle Cell Disease. Biology of blood and marrow transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2010;16:S253.

77.    Walter, PB, Weyhmiller, Lal A, Harmatz, P and Vichinsky E. Understanding Iron Transport and Iron Metabolism in Sickle Cell Disease and Thalassemia. International Advanced Workshop on Sickle Cell Disease. Oakland, CA, USA, Oct 28-29, 2010.

78.    Walter, PB, Weyhmiller M, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Grady RW, Olivieri NF, Trachtenberg F, Lal A, Vichinsky E, and Harmatz, P. Oxidants, Inflammation and Innate Immune Function in Iron Overloaded Thalassemia Patients: Effect of Chelation. 20th International Conference on Chelation. Grand Rapids, MI, USA, 2010.

date revised: 9/22/2011